The Studio365 mobile app by Live365 mobile app enables broadcasters to manage their radio stations anywhere they go. With the Studio365 mobile app you can: • Create, preview, and manage your Shout Out Messages • Set and update your pre-rolls and station ID messages • Update your profile including title, image, description, etc. • Check your listener stats in real time • Listen and share your station anywhere New features coming soon To
use the Studio365 app, a Live365 broadcasting account is required. To
learn more about broadcasting with Live365, and to get a free 7 day
personal broadcasting trial using the Live365 platform, visit
http://www.live365.com/dj
http://www.greatsouthernoutdoors.com/book_a_hunt/quail_hunting/ Sweet Home Alabama Quail Hunting Great Southern Outdoors prides itself being located in the region known as the Field Trial Capital of the World. Quail hunting in this area has been a gentlman's sport since the 1800′s when plantation owners would get involved in friendly competition. Now it has become a well liked sport by both outdoors-men and women. Great Southern Outdoors quail staff, Josh, Mark, Freeman, and Hunter enjoy the sport as much as our hunters and a little friendly competition only makes it more exciting.You are sure to have an experience of a lifetime just watching the dogs work and being in the Great Southern Outdoors.
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
The Alfred Mann Foundation (AMF) today announced the first subject, a U.S. Marine, SSgt James Sides, as a recipient of its highly anticipated IMES System (implantable myoelectric sensor) – an experimental system that holds the promise of being the first minimally invasive, intuitive, multi-channel control system for prosthetics intended for long term use. The IMES System is currently being studied under the Investigational Device Exemption (IDE) regulations of the U.S. Food and Drug Administration (FDA). AMF’s ongoing trial with injured veterans at the Walter Reed National Medical Military Center anticipates subjects intuitively operating three different prosthetic movements simultaneously: opening and closing the hand, rotating the wrist, and moving the thumb. Combining these three movements enables several grasps that are invaluable for performing everyday tasks.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65112-alfred-mann-foundation-u-s-marine-subject-fda-study-for-imes-system
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Turn Your Dull Pictures Taken from Mobile into Vibrant Pics That Speak a Million Words. Learn For Free, Few Chapters Are Being Taught by a 9 year Old 5th Grade Girl, Which Has Become the Talking Point of Media Worldwide. Watch the Preview Promo to know different ways of how you can make your pictures stunning enough to post on the Social Media. A 9 year old 5th grade girl teaches you few amazing tricks that can transform your pictures instantly. Before experimenting any new look at beauty salon, you can first try it on your photograph. Now pimples & acne can't hide the actual beauty of yours, learn how to make your pimples & acne do the vanishing act on your photograph With RK Photo magic trix. Use Trial & Error methods to find out which colors of your Lipstick, Eye Shadow, Tattoo, Blush On, Mehndi, Dress Color & Hairstyle looks best on you, also learn to do extreme make up on your photographs. Listen to the peppy African Theme song recorded in Africa & Sung by an African. A fifth standard girl Arkshya Raj Kalra along with her father is teaching some interesting & simple tricks of Photoshop & in the process the International Media has already started talking & writing about this simplified tutorials aimed at rectifying the problems that everyone faces in their pictures. For more updates and Photo Trix ... like RKPhotoMagicTrix Facebook page --
https://www.facebook.com/rkphotomagictrix
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
A recently published scientific study from Lund University by lead researcher Charlotte Erlanson-Albertsson, MD, PhD found that subjects who were trying to lose weight and used the patented spinach extract Appethyl on a daily basis lost 43 percent more weight compared to those ingesting a placebo.
In this clinical trial, overweight women were given either a daily five gram dose of Appethyl or a control drink immediately before breakfast. Researchers found that the weight of the women ingesting Appethyl decreased significantly at 43 percent more than subjects ingesting the control drink.
This is one of three studies that also compared the effects of Appethyl after 90 days with those found after the first dose and found no decline of effects, indicating that Appethyl takes effect after the first dose and is just as effective after long-term use. One study showed that Appethyl reduced hunger by 25 percent four hours after consumption, in addition to reducing thoughts about food by 33 percent.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7426951-appethyl-spinach-extract/
Off the coast of Central America, the Sea Diva, a tuna boat, sinks. Members of the crew are missing and what happened remains a mystery. As the case goes to trial, a missing crew member is believed to be at fault, but new evidence comes to light and the finger of guilt points in a completely unanticipated direction. Learn more here: http://bit.ly/1LHfMJ0
World trade in perishable foods turns a page as Maersk Container Industry (MCI), an independent business unit in the Maersk Group conglomerate, today announced that it has begun production of the first refrigerated containers and Star Cool refrigeration machines built in South America at its new MCI facility in San Antonio, Chile.
The first trial production of these ISO standard 40 feet reefer containers were successfully delivered during the third quarter of 2015 into the Maersk Line and CMA CGM operations. Shortly thereafter, both shipping lines placed new orders. To further leverage this new value proposition, Maersk Line has secured a fixed monthly volume from the MCI facility allowing for increased agility and fast response time to the demand in the region.
“In this sweet spot of fruit exporters, we have placed the factory right where the demand is. For the first time ever in South America, reefer containers can go straight “from factory to farm”,” said Stig Hoffmeyer, Chief Executive Officer of MCI. “Offering the Star Cool Integrated reefers locally to shipping lines, farmers, fruit distributors and leasing companies, will have a financial benefit counted in thousands of dollars per reefer, and millions for the industry in total,” he continued.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7688551-maersk-container-industry-factory-chile/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/